Functional VEGF haplotypes affect the susceptibility to hypertension

Journal of Human Hypertension

Volumn 27, Issue 1, 2013, Pages 31-37

  Sandrim, V C ^a   Luizon, M R ^b   Izidoro Toledo, T C ^b   Coelho, E B ^b   Moreno, H ^c   Tanus Santos, J E ^b  

^a Nucleo de Pos Graduacao e Pesquisa   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

haplotypes; nitric oxide; NOx; polymorphisms; VEGF

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENOMIC DNA; NITRATE; NITRIC OXIDE; NITRITE; VASCULOTROPIN;

ADULT; ALLELE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD LEVEL; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870788526     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.110     Document Type: Article

References (47)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-676.
2. Hutchings H, Ortega N, Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. Faseb J 2003; 17(11): 1520-1522.
3. Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Crosssectional data from the SAPHIR study. Atherosclerosis 2009; 206: 265-269.
4. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999; 274(35): 25130-25135.
5. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49(10): 1015-1026.
6. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G et al. Vascular endothelial growth factor genotypes and haplotypes are associated with preeclampsia but not with gestational hypertension. Mol Hum Reprod 2009; 15(2): 115-120.
7. Girnita DM, Webber SA, Ferrell R, Burckart GJ, Brooks MM, McDade KK et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 2006; 82(12): 1774-1780.
8. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34(4): 383-394.
9. Goncalves FM, Martins-Oliveira A, Speciali JG, Izidoro-Toledo TC, Luizon MR, Dach F et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in women with migraine. DNA Cell Biol 2010; 29(7): 357-362.
10. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265(2 Part 2): H586-H592.
11. Wei W, Jin H, Chen ZW, Zioncheck TF, Yim AP, He GW. Vascular endothelial growth factor-induced nitric oxide-and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol 2004; 44(5): 615-621.
12. Liu MH, Jin HK, Floten HS, Yang Q, Yim AP, Furnary A et al. Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. J Pharmacol Exp Ther 2001; 296(2): 473-477.
13. Vyzantiadis T, Karagiannis A, Douma S, Harsoulis P, Vyzantiadis A, Zamboulis C. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin Exp Hypertens 2006; 28(7): 603-609.
14. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84(24): 9265-9269.
15. Thomas GD, Zhang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. Jama 2001; 285(16): 2055-2057.
16. Muniz JJ, Izidoro-Toledo TC, Metzger IF, Sandrim VC, Tanus-Santos JE. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol 2009; 28(11): 567-572.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 2003; 289(19): 2560-2572.
18. Nagassaki S, Metzger IF, Souza-Costa DC, Marroni AS, Uzuelli JA, Tanus-Santos JE. eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb Res 2005; 115(5): 375-379.
19. Sandrim VC, de Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE. Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 2007; 16(3): 348-355.
20. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70(2): 425-434.
21. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos JE. Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 2006; 186(2): 428-432.
22. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med 2005; 56: 303-320.
23. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2(2): 91-99.
24. Kaufman JS. How inconsistencies in racial classification demystify the race construct in public health statistics. Epidemiology 1999; 10(2): 101-103.
25. Palmirotta R, Ferroni P, Ludovici G, Martini F, Savonarola A, D'Alessandro R et al. VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin Biochem 2010; 43(13-14): 1090-1095.
26. Kaplan NM. Resistant hypertension. J Hypertens 2005; 23(8): 1441-1444.
27. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005; 258(4): 336-343.
28. Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci (Lond) 2005; 109(1): 39-43.
29. Ayerden Ebinc F, Haksun E, Ulver DB, Koc E, Erten Y, Reis Altok K et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med 2008; 47(17): 1511-1516.
30. Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998; 18(6): 3112-3119.
31. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998; 17(2): 227-236.
32. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63(4): 812-816.
33. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399(6736): 601-605.
34. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
35. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100(14): 8372-8377.
36. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003; 14(8): 709-714.
37. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792-799.
38. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56(6): 1131-1136.
39. Rhodes P, Leone AM, Francis PL, Struthers AD, Moncada S, Rhodes PM. The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1995; 209(2): 590-596.
40. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349(9055): 837-842.
41. Tsuda K, Nishio I. Leptin and nitric oxide production in normotensive and hypertensive men. Obes Res 2004; 12(8): 1223-1237.
42. Silva PS, Fontana V, Palei AC, Sertorio JT, Biagi C, Tanus-Santos JE. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Eur J Clin Pharmacol 2011; 67(4): 365-370.
43. Kelm M, Feelisch M, Deussen A, Strauer BE, Schrader J. Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc Res 1991; 25(10): 831-836.
44. Kohno M, Yokokawa K, Minami M, Yasunari K, Maeda K, Kano H et al. Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Metabolism 1999; 48(10): 1256-1259.
45. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 2006; 41(7): 1044-1049.
46. Metzger IF, Sertorio JT, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf) 2006; 188(2): 123-127.
47. Metzger IF, Sertorio JT, Tanus-Santos JE. Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 2007; 43(6): 987-992.